← All trials
NCT04483960
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 28, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2022
- First posted
- Jul 23, 2020
- Last posted
- Nov 23, 2020
- Enrollment
- 2400
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MelbourneLead sponsor
- The Peter Doherty InstituteCollaborator
- University of MelbourneReponsible party - principal investigator
- Melbourne HealthStudy chair
- Australasian Society for Infectious DiseasesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.